Search results
Here's Why Merck (MRK) Stock Has Outperformed Industry YTD
Zacks via Yahoo Finance· 5 days agoMerck MRK boasts more than six blockbuster drugs in its portfolio, with PD-L1 inhibitor Keytruda...
AstraZeneca’s $80B sales plan leans on cancer drug expansion
BioPharma Dive via Yahoo Finance· 4 days agoThe company claims it can make that drug, which would compete with Legend and J&J’s Carvykti and...
ASCO24: An early look at cancer drug study results
BioPharma Dive via Yahoo Finance· 2 days agoClinical trial abstracts posted Thursday ahead of this year’s ASCO meeting give a peek at anticipated datasets from Immunocore, Merus, J&J and Merck &...
Immunotherapy for stomach cancer: Types and effectiveness
Medical News Today· 3 days agoImmunotherapy may help shrink a tumor or slow the growth of cancer cells. People may have it in...
Why Merck (MRK) is a Top Momentum Stock for the Long-Term
Zacks via Yahoo Finance· 3 days agoKeytruda has played an instrumental role in driving Merck’s steady revenue growth in the past few...
Billionaire Ken Griffin Is Buying These Dividend Stocks Hand Over Fist. Should You?
Motley Fool via Yahoo Finance· 2 days agoThe company picked up new U.S. and European approvals for blockbuster drug Keytruda. It announced...
Is Merck & Co., Inc. (NYSE:MRK) the Best Dow Stock To Buy According to Hedge Funds?
Insider Monkey via Yahoo Finance· 6 hours agoWe recently identified the best dow stocks according to hedge funds. Even though Merck & Co., Inc....
S&P 500 Plays And Dow Giant Lead 5 Stocks Near Buy Points
Investor's Business Daily· 13 hours agoThese five names are showing relative strength.
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024
FOX 23 News Albany· 3 days agoEisai announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American Society of Clinical Oncology ...
Medicenna to Present Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming Sachs 10th Annual...
Digital Journal· 4 days agoMedicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that it ...